▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent Articles by Maxx Chatsko

256 investing gift

Aug 28, 2019 by Maxx Chatsko, Jason Hall, and Matt DiLallo

3 Stocks to Buy and Hold for Decades

These businesses offer the potential for above-average returns that could receive a huge helping hand from the power of compound interest.

green chart growth

Aug 27, 2019 by Maxx Chatsko

Here's Why Silver Stocks Are Soaring Again Today

The precious metal has been rising in price as global economic headwinds mount.

026 question mark on wooden table

Aug 27, 2019 by Maxx Chatsko

Iovance Biotherapeutics: Buy the Dip?

The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?

multiple lines down

Aug 27, 2019 by Maxx Chatsko

Here's Why Mallinckrodt Fell Over 17% Today

The bad news keeps piling up.

stock down finger

Aug 23, 2019 by Maxx Chatsko

Here's Why Oil and Gas Stocks Are Getting Crushed Today

China has decided that American oil exports, a relative strength in recent years, are fair game in the trade war.

449 pool raft

Aug 23, 2019 by Maxx Chatsko, Demitri Kalogeropoulos, and Brian Feroldi

3 Top Growth Stocks to Buy in the Final Month of Summer

The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.

247 doctor knee exam

Aug 22, 2019 by Maxx Chatsko

Unity Biotech: Buy at the Low?

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

arrow up shelves

Aug 21, 2019 by Maxx Chatsko

Arrowhead Pharmaceuticals: Buy at the High?

Shares are trading hands at their highest level in years, and have posted a three-year return of over 350%.

026 question mark on wooden table

Aug 20, 2019 by Maxx Chatsko

Deciphera Pharmaceuticals: Buy at the High?

Investors have run back to the stock after promising clinical results.

046 dna model

Sep 16, 2019 by Maxx Chatsko

Twist Bioscience Grows Q3 Revenue 108%, but Losses Pile Up

The business reported an operating loss of $77 million in the first nine months of fiscal 2019.

291 man exercise

Aug 18, 2019 by Maxx Chatsko, Jason Hall, and Matt DiLallo

3 Dividend Stocks Ideal for Retirees

These income stocks can make your retirement funds go even further.

302 growth stock

Aug 17, 2019 by Maxx Chatsko, Demitri Kalogeropoulos, and Brian Feroldi

3 High-Growth Stocks That Are Just Getting Started

Inject a little (or a lot) of growth into your portfolio with these three companies.

192 biotech lab

Aug 16, 2019 by Maxx Chatsko

Agilent Keeps Analysts Guessing, Beats Estimates in Q3

The company has revised guidance in each of the last four quarters, but it continues to outperform expectations.

stock up bar chart getty

Aug 16, 2019 by Maxx Chatsko

Here's Why Solid Biosciences Is Soaring Today

The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?

227 potted plant arrow

Aug 16, 2019 by Maxx Chatsko, Demitri Kalogeropoulos, and Brian Feroldi

3 Growth Stocks for In-the-Know Investors

Investors looking to grow their nest egg should give these three stocks a closer look.

raining cash getty

Aug 15, 2019 by Maxx Chatsko

Here's Why Agilent Technologies Rose as Much as 10.8% Today

The lab hardware company reported fiscal third-quarter 2019 operating results.

stock sliding chalkboard

Aug 15, 2019 by Maxx Chatsko

Here's Why Gold Fields Fell as Much as 10.8% Today

The gold miner delivered a solid performance in the first half of 2019, but investors are remaining cautious.

biotech down

Aug 15, 2019 by Maxx Chatsko

Myriad Genetics Limps Into Fiscal 2020

A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.

chalkboard stock down pink

Aug 14, 2019 by Maxx Chatsko

Here's Why Myriad Genetics Is Getting Crushed Today

The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.

stock down angry fist

Aug 14, 2019 by Maxx Chatsko

Here's Why Bloom Energy Collapsed Today

The fuel cell company told investors to expect no growth in 2020.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services